Liberum Capital Reiterates Hold Rating for Shire (SHP)
Liberum Capital reissued their hold rating on shares of Shire (LON:SHP) in a research report report published on Wednesday. The firm currently has a GBX 4,000 ($55.26) price target on the biopharmaceutical company’s stock.
Other analysts also recently issued research reports about the stock. Barclays assumed coverage on shares of Shire in a report on Thursday, February 1st. They set an equal weight rating for the company. Credit Suisse Group decreased their price objective on shares of Shire from GBX 4,500 ($62.17) to GBX 4,000 ($55.26) and set an outperform rating for the company in a report on Thursday, February 15th. Kepler Capital Markets restated a buy rating and set a GBX 4,600 ($63.55) price objective on shares of Shire in a report on Thursday, February 15th. Shore Capital restated a buy rating on shares of Shire in a report on Friday, February 23rd. Finally, Citigroup restated a buy rating and set a GBX 5,500 ($75.99) price objective on shares of Shire in a report on Friday, December 8th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of GBX 4,955.88 ($68.47).
Shares of Shire (SHP) opened at GBX 3,192.50 ($44.11) on Wednesday. Shire has a 1-year low of GBX 2,940.50 ($40.63) and a 1-year high of GBX 5,021 ($69.37). The stock has a market cap of $29,080.00 and a PE ratio of 2,186.64.
In other Shire news, insider Dominic Blakemore bought 165 shares of the business’s stock in a transaction on Tuesday, December 19th. The stock was purchased at an average price of GBX 3,790 ($52.36) per share, for a total transaction of £6,253.50 ($8,639.82).
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.